First Light Asset Management LLC Has $32.46 Million Stock Position in Insmed Incorporated (NASDAQ:INSM)

First Light Asset Management LLC cut its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 31.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 470,192 shares of the biopharmaceutical company's stock after selling 218,718 shares during the quarter. Insmed comprises approximately 3.1% of First Light Asset Management LLC's holdings, making the stock its 13th largest position. First Light Asset Management LLC owned about 0.26% of Insmed worth $32,462,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in shares of Insmed during the 4th quarter valued at about $47,000. Smartleaf Asset Management LLC raised its stake in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in Insmed in the 4th quarter worth approximately $86,000.

Insmed Price Performance

Shares of INSM traded down $0.34 during mid-day trading on Friday, reaching $72.30. The company had a trading volume of 1,600,638 shares, compared to its average volume of 2,309,884. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market capitalization of $13.15 billion, a P/E ratio of -12.93 and a beta of 1.07. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company's 50-day moving average is $73.42 and its 200-day moving average is $73.48.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the sale, the chief executive officer now owns 379,534 shares of the company's stock, valued at $29,580,879.96. This represents a 4.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 33,055 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the transaction, the insider now owns 138,053 shares in the company, valued at $11,168,487.70. The trade was a 19.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 387,487 shares of company stock worth $30,825,692. Insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Tuesday, April 22nd. Bank of America upped their price target on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Finally, Stifel Nicolaus lowered their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.